Once-weekly insulin icodec more beneficial than once-daily insulin degludec for treating type 2 diabetes

By Editor
22nd September 2022
Research, Type 2 diabetes

More than 36 per cent of adults with type 2 diabetes treated with once-weekly insulin icodec achieved an HbA1c <7.0%, according to new data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2022.

Meanwhile, only 26.8 per cent of adults treated with insulin degludec achieved an HbA1c <7.0%, Novo Nordisk has reported.

Insulin icodec is an investigational medicine that is not currently licensed for use in the UK.

Dr Athena Philis-Tsimikas, principal investigator of ONWARDS 2, said: “Once-weekly insulin would be a remarkable step forward in insulin innovation.

“It could offer people with type 2 diabetes reduced treatment complexity and burden by reducing the number of basal insulin injections from 365 to 52 per year, without compromising management of blood sugar.”

The trial achieved its primary endpoint of demonstrating non-inferiority in reducing HbA1c at week 26 with insulin icodec (n=263) compared with insulin degludec (n=263).

From a mean baseline of 8.17% (icodec) and 8.10% (degludec), once-weekly insulin icodec achieved a superior reduction in estimated HbA1c of 0.93% compared with 0.71% for insulin degludec ([95% CI, -0.37- -0.08]; p=0.0028).

People with diabetes in ONWARDS 2 reported significantly greater satisfaction in favour of once-weekly insulin icodec compared with insulin degludec at 26 weeks as assessed by the Diabetes Treatment Satisfaction Questionnaire (DTSQ).

The mean weekly insulin dose was 268 U/week for insulin icodec vs 244 U/week for insulin degludec.

The estimated mean change in body weight from baseline to week 26 was 1.40 kg for insulin icodec compared with –0.30 kg for insulin degludec ([95% CI, 0.76;2.63]; p<0.001).

In the trial, once-weekly insulin icodec appeared to have a generally well-tolerated safety profile.

There was less than one hypoglycaemic event per patient-year exposed for insulin icodec and insulin degludec (0.73 events and 0.27 events per patient-year exposed, respectively, with no statistically significant difference between arms) ([95% CI, 0.93, 4.02]; p=0.0782).

As previously reported, no severe hypoglycaemia events were observed for people treated with insulin icodec.

Comments (0)

Register an account or login to comment